Neuroleptic-induced parkinsonism is the second most common drug-induced movement disorder after akathisia and remains a leading reason for antipsychotic discontinuation and nonadherence. The DSM-5-TR codes it under medication-induced movement disorders (code G21.11 for neuroleptic-induced and G21.19 for other medication-induced parkinsonism), reflecting striatal D2 receptor blockade by typical and, less commonly, atypical antipsychotics. Clinically it mimics idiopathic Parkinson disease — bradykinesia, rigidity, and a coarse postural tremor — but tends to be more symmetric, more rapid in onset, and reversible once the offending agent is removed. Misrecognition has two costs: continued exposure that worsens function and adherence, and false attribution of symptoms to a primary neurodegenerative disease. The clinician's job is to recognize early, reduce dopamine blockade where possible, and avoid layering anticholinergic burden in older adults.

Drug-induced parkinsonism accounts for a substantial fraction of parkinsonism diagnosed in psychiatric and geriatric populations, and its frequency tracks the potency of dopamine blockade.^[1-2] Older epidemiologic data place it second only to idiopathic Parkinson disease as a cause of parkinsonism in primary care settings.^[2]

Frequency on antipsychotics

• Reported incidence ranges from 15% to 40% on first-generation antipsychotics, with high-potency agents (haloperidol, fluphenazine) at the upper end.^[1,3]
• Second-generation agents carry lower but non-trivial risk; risperidone above 6 mg/day approaches first-generation rates, while quetiapine and clozapine carry the lowest signal.^[3-4]
• Among older adults newly started on any antipsychotic, parkinsonism develops in roughly one-third within three months of initiation.^[2]

Risk factors

• Age above 60 years — the single strongest demographic predictor, reflecting age-related nigral neuron loss reducing reserve.^[2,5]
• Female sex, with an approximately 2:1 ratio in most cohorts.^[1,5]
• Higher antipsychotic dose and higher D2 receptor occupancy (above 78-80% striatal occupancy on PET).^[6]
• Concomitant use of other dopamine-blocking agents, notably metoclopramide and prochlorperazine.^[7]
• Subclinical neurodegeneration — patients who develop drug-induced parkinsonism have higher rates of subsequent conversion to idiopathic Parkinson disease, suggesting the drug unmasks latent disease in a subset.^[8]
• Prior traumatic brain injury and other CNS insults have been reported as risk factors in case-control work, though evidence is mixed.^[2]

Non-antipsychotic offenders

• Antiemetics with D2 antagonism: metoclopramide, prochlorperazine, promethazine.^[7]
• Calcium channel blockers with dopaminergic activity: flunarizine and cinnarizine (not marketed in the United States but common in Europe, Latin America, and parts of Asia).^[10]
• Tetrabenazine, valbenazine, and deutetrabenazine — vesicular monoamine transporter type 2 (VMAT2) inhibitors used for tardive dyskinesia and Huntington chorea.^[11]
• Lithium and valproate produce a tremor-predominant picture that can be mistaken for parkinsonism but typically lack bradykinesia.^[12]

The proximate mechanism is postsynaptic D2 receptor blockade in the nigrostriatal pathway, producing a functional dopamine-deficient state that phenocopies idiopathic Parkinson disease.^[6,13] Symptoms emerge when striatal D2 occupancy exceeds roughly 78-80%, the same threshold above which antipsychotic efficacy plateaus but EPS rise sharply.^[6]

Pharmacologic basis

• High-potency D2 antagonists (haloperidol, fluphenazine, risperidone at higher doses) exceed the EPS threshold at typical clinical doses.^[3,6]
• Clozapine and quetiapine produce relatively transient D2 occupancy and dissociate rapidly from the receptor, accounting for their low parkinsonism rates.^[4,13]
• Aripiprazole, brexpiprazole, and cariprazine are D2 partial agonists; they can still produce parkinsonism but at lower rates and via a different occupancy profile.^[14]

Neuroanatomy

• The nigrostriatal pathway projects from the substantia nigra pars compacta to the dorsal striatum; D2 blockade here disinhibits the indirect pathway, reducing thalamocortical drive and producing bradykinesia and rigidity.^[13]
• In contrast to idiopathic Parkinson disease, presynaptic dopamine synthesis and terminal density are preserved — the basis for normal DaT-SPECT imaging in pure drug-induced cases.^[8,15]

Why some patients are vulnerable:

• Age-related loss of nigral neurons (approximately 5-10% per decade after age 60) reduces the threshold at which D2 blockade becomes symptomatic.^[5]
• Polymorphisms in DRD2 and CYP2D6 may influence individual susceptibility, though evidence remains preliminary.^[16]
• Patients with prodromal Parkinson disease (hyposmia, REM sleep behavior disorder) are at elevated risk and may convert to idiopathic disease after drug withdrawal.^[8]

DSM-5-TR classifies neuroleptic-induced parkinsonism among medication-induced movement disorders, requiring parkinsonian signs that develop in temporal relation to neuroleptic exposure or to dose escalation.^[17] ICD-11 codes the same syndrome under 8A00.2 (secondary parkinsonism), with extension codes specifying the offending medication.^[18]

Core DSM-5-TR features

• Parkinsonian tremor, muscular rigidity, akinesia, or bradykinesia developing within a few weeks of starting, increasing, or switching to a neuroleptic medication.^[17]
• The symptoms cause clinically significant distress or functional impairment.^[17]
• Symptoms are not better explained by another movement disorder (e.g., Parkinson disease) or another medical condition.^[17]

Course modifiers and clinical anchors

• Onset is typically within days to three months of drug initiation or dose increase; later onset still qualifies if the temporal link is clear.^[1,17]
• Resolution usually occurs within weeks to months of discontinuation, though up to 10-15% have persistent symptoms beyond 6 months, raising concern for unmasked idiopathic Parkinson disease.^[8,19]
• No formal severity rating is required for DSM-5-TR coding; the Simpson-Angus Scale and the motor subscale of the UPDRS (now MDS-UPDRS Part III) are the workhorses in clinical and research settings.^[20-21]

ICD-11 nuance

• ICD-11 separates secondary parkinsonism (8A00.2) from neuroleptic malignant syndrome and other movement complications, reflecting cleaner mechanistic groupings than ICD-10.^[18]

The presentation overlaps substantially with idiopathic Parkinson disease but carries several distinguishing features that the bedside examiner can usually elicit. Symptom emergence days to weeks after a dopamine blocker is the single most useful historical clue.^[1,17]

Cardinal motor features

• Bradykinesia: slowness of movement initiation and execution, hypomimia (reduced facial expression), micrographia, hypophonia, and reduced arm swing during gait.^[20]
• Rigidity: increased tone throughout passive range of motion; cogwheeling reflects superimposed tremor on the rigidity.^[20]
• Tremor: typically a coarse 3-6 Hz postural and action tremor; classic pill-rolling resting tremor occurs but is less common than in idiopathic disease.^[1,20]
• Postural instability: late finding; positive pull test indicates significant disease.^[20]

Features that favor drug-induced over idiopathic disease:

• Symmetric onset and progression — idiopathic Parkinson disease is famously asymmetric in its first years.^[1,8]
• Acute or subacute onset over days to weeks rather than insidious progression over months to years.^[1]
• Prominent postural and action tremor with relatively preserved resting tremor.^[1]
• Concurrent orofacial dyskinesia or tardive features in a patient on chronic neuroleptics — suggests the broader EPS spectrum is at play.^[22]
• Improvement after drug withdrawal or anticholinergic challenge.^[1,19]

Non-motor features

• Bradyphrenia and apathy can be drug-related but also accompany idiopathic Parkinson disease.^[20]
• Autonomic features (orthostasis, constipation) and olfactory loss are more characteristic of idiopathic disease.^[8]
• REM sleep behavior disorder is a prodromal marker of idiopathic Parkinson disease; its presence in a patient with apparent drug-induced parkinsonism raises concern for unmasked primary disease.^[8]

The clinical question is rarely "is this parkinsonism" but rather "is this drug-induced, idiopathic, or something else." A careful medication review and timeline are diagnostically more useful than any single examination finding.^[1,8]

Idiopathic Parkinson disease

• Asymmetric onset, insidious progression, prominent resting tremor, hyposmia, REM sleep behavior disorder, and sustained levodopa response.^[8]
• DaT-SPECT shows reduced striatal dopamine transporter binding; normal scan in a patient with parkinsonism on a dopamine blocker supports drug-induced etiology.^[15]

Other extrapyramidal syndromes from antipsychotics

• Acute dystonia — sudden sustained muscle contractions (oculogyric crisis, torticollis) within hours to days of drug exposure, most common in young men.^[22]
• Akathisia — subjective restlessness with motor manifestations; not parkinsonism but frequently coexists and is often misidentified.^[22]
• Tardive dyskinesia — choreoathetoid orofacial and limb movements emerging after months to years; distinct mechanism (D2 receptor supersensitivity).^[22]
• Neuroleptic malignant syndrome — fever, severe rigidity, autonomic instability, and altered mental status; a medical emergency, not a differential for chronic parkinsonism.^[23]

Medical mimics

• Hypothyroidism — bradykinesia, masked facies; check TSH.^[24]
• Wilson disease — in patients under 50, check ceruloplasmin and 24-hour urine copper.^[25]
• Normal pressure hydrocephalus — magnetic gait, urinary incontinence, cognitive impairment; imaging confirms.^[24]
• Vascular parkinsonism — lower-body predominant, stepwise progression, vascular risk factors, white matter disease on imaging.^[24]
• Progressive supranuclear palsy and multiple system atrophy — atypical parkinsonian syndromes with early postural instability, vertical gaze palsy, or autonomic failure.^[24]

Substance-related causes

• MPTP exposure — historical relevance from contaminated meperidine analogs; produces irreversible parkinsonism via complex I inhibition.^[26]
• Manganese toxicity in welders and methcathinone ("bath salts") users.^[26]

Diagnosis rests on a careful drug timeline, neurologic examination, and selective use of imaging when the picture is atypical. Most cases are diagnosed clinically without laboratory confirmation.^[1,19]

History elements that should not be omitted:

• Complete medication review including over-the-counter antiemetics, antivertigo agents (cinnarizine, flunarizine where available), and recent dose changes.^[7,10]
• Timeline of symptom onset relative to drug start, dose change, or formulation switch (e.g., long-acting injectable initiation).^[1]
• Family history of Parkinson disease, essential tremor, or other movement disorders.^[8]
• Prodromal features of idiopathic disease: hyposmia, REM sleep behavior disorder, constipation, depression preceding motor symptoms.^[8]

Examination

• Full motor examination with attention to symmetry, tremor at rest versus posture and action, bradykinesia testing (finger tapping, hand opening/closing, foot tapping), and rigidity in upper and lower limbs.^[20]
• Gait observation: stride length, arm swing, turning, freezing.^[20]
• Pull test for postural instability.^[20]
• Inspect for orofacial dyskinesia or other tardive features.^[22]

Validated rating scales

• Simpson-Angus Scale — 10-item clinician-rated scale specific for drug-induced parkinsonism; a score above 3 (or any item rated 2 or higher) is clinically meaningful.^[20]
• MDS-UPDRS Part III — motor examination subscale of the unified Parkinson disease rating scale; widely used in idiopathic disease but applicable to drug-induced cases.^[21]
• Abnormal Involuntary Movement Scale (AIMS) — for accompanying tardive dyskinesia, not parkinsonism itself.^[22]

Laboratory and imaging

• Routine first-line workup: TSH, CBC, electrolytes, vitamin B12, and liver function.^[24]
• In patients under 50: ceruloplasmin and 24-hour urine copper to exclude Wilson disease.^[25]
• MRI brain when the presentation is atypical (asymmetric, rapidly progressive, focal signs) to evaluate for vascular disease, normal pressure hydrocephalus, or structural lesions.^[24]
• DaT-SPECT (ioflupane I-123) distinguishes pre-synaptic dopaminergic deficit (idiopathic disease) from normal pre-synaptic function (pure drug-induced); reserve for diagnostically challenging cases.^[15]

What not to order

• Routine genetic testing for parkinsonism in the absence of family history or young onset.^[8]
• Levodopa challenge as a diagnostic test outside specialized movement disorder settings — false positives and negatives are common.^[19]

Management follows a clear hierarchy: address the offending agent first, then add symptomatic treatment only when dose modification is impossible or inadequate. Anticholinergics are widely used but carry meaningful harms in older adults, and routine prophylaxis is no longer recommended.^[19,27]

Pharmacotherapy

• First step is reduction of the offending agent to the lowest effective dose; in many patients this resolves symptoms within weeks without adding new medications.^[1,19]
• When dose reduction is insufficient or impossible, switch to a lower-EPS-risk antipsychotic — quetiapine, clozapine, or aripiprazole are common choices depending on the underlying indication.^[3-4,28]
• First-line symptomatic agent is an anticholinergic such as benztropine 0.5-2 mg PO BID or trihexyphenidyl 2-5 mg PO TID, when dose reduction is impossible.^[19,27]
• amantadine 100 mg PO BID is an alternative, particularly in older adults where anticholinergic burden is a concern; it acts via NMDA antagonism and dopamine release.^[27,29]
• Levodopa is rarely useful in pure drug-induced parkinsonism because the postsynaptic D2 receptor is blocked; it is reserved for patients with concurrent idiopathic disease unmasked by drug exposure.^[19]
• Routine anticholinergic prophylaxis at antipsychotic initiation is not recommended due to cognitive harms and lack of mortality benefit; reserve for high-risk patients (young men on high-potency agents, prior dystonia).^[27]

Psychotherapy

• Adherence-focused interventions matter because parkinsonism is a leading reason for antipsychotic nonadherence; psychoeducation that reframes EPS as treatable rather than inevitable improves outcomes.^[31]
• Cognitive behavioral therapy and supportive therapy do not treat parkinsonism directly but address the secondary depression and functional impairment that often follow.^[31]

Neuromodulation

• ECT can transiently improve parkinsonism in patients with comorbid depression, but the effect is not durable and ECT is not indicated as primary treatment.^[32]
• Deep brain stimulation has no role in drug-induced parkinsonism; persistent symptoms after adequate drug withdrawal warrant reassessment for idiopathic disease.^[19]

Adjunctive

• Physical therapy with gait training and balance work reduces falls and preserves function during symptomatic recovery.^[33]
• Occupational therapy assists with adaptive strategies for micrographia, dressing, and self-care.^[33]
• Vitamin D and calcium supplementation are reasonable in older adults given fall and fracture risk.^[33]

Treatment-resistant cases

• Persistent parkinsonism after 6 months of drug withdrawal warrants neurology referral and consideration of DaT-SPECT to evaluate for unmasked idiopathic Parkinson disease.^[8,15,19]
• In schizophrenia patients who require continued antipsychotic treatment and cannot tolerate alternatives, clozapine has the lowest parkinsonism rate and should be considered when criteria are met.^[4,28]

The harms of drug-induced parkinsonism are both direct (motor disability, falls, aspiration) and indirect (nonadherence to needed psychiatric medication, misdiagnosis as idiopathic disease). The harms of treatment, particularly anticholinergic exposure in older adults, are non-trivial and frequently underweighted.^[27,30]

Common harms

• Falls and fall-related fractures, particularly in older adults with comorbid parkinsonism.^[5,33]
• Functional decline in activities of daily living, often persisting weeks after motor symptoms improve.^[33]
• Reduced quality of life and contribution to depression, especially when symptoms are dismissed by clinicians.^[31]

Serious or rare harms

• Aspiration pneumonia from oropharyngeal dysfunction in severe cases.^[33]
• Anticholinergic delirium in older adults on benztropine or trihexyphenidyl, particularly when combined with other anticholinergic burden.^[9,30]
• Worsening of underlying tardive dyskinesia with anticholinergic addition.^[22,27]
• Rare reports of withdrawal-emergent worsening when benztropine is stopped abruptly after months of use.^[27]

Monitoring burden and limitations of evidence

• Regular Simpson-Angus or MDS-UPDRS Part III assessment is recommended on chronic antipsychotics but is inconsistently performed in practice.^[20-21]
• Most trials enrolled patients with schizophrenia in their 30s and 40s; data in older adults, perinatal women, and patients with neurocognitive disorders are limited.^[2,5]
• Long-term outcome data on conversion to idiopathic Parkinson disease after drug withdrawal remain modest, with cohort estimates of 10-20% over 5 years.^[8,19]
• Publication bias likely overstates anticholinergic efficacy; head-to-head trials against dose reduction alone are scarce.^[27]

Risk-benefit calculations shift in older adults, perinatal women, and patients with comorbid neurologic disease. The general principle — lowest effective dose of the lowest-EPS-risk agent — applies but with population-specific modifications.^[2,28]

Older adults

• Higher baseline risk reflects age-related nigral neuron loss and increased pharmacokinetic vulnerability.^[2,5]
• Anticholinergic agents are relatively contraindicated due to delirium and cognitive harm; amantadine or dose reduction is preferred.^[27,30]
• The American Geriatrics Society Beers Criteria list both first-generation antipsychotics and benztropine as potentially inappropriate in adults 65 and older.^[30]

Perinatal

• Antipsychotic-treated pregnant women have an elevated rate of EPS in the neonate, including transient parkinsonism in infants exposed in the third trimester.^[34]
• Where antipsychotic treatment is required, choosing a lower-EPS-risk agent (quetiapine, olanzapine) and avoiding anticholinergics when possible is reasonable; specialist consultation is recommended.^[34]

Pediatric and adolescent

• Children and adolescents are at increased risk for acute dystonia and parkinsonism per kg of dopamine blockade compared to adults, though absolute rates depend on the agent.^[35]
• Pediatric prescribing should favor agents with FDA pediatric indications and start at low doses with frequent monitoring.^[35]

Patients with major neurocognitive disorder

• Patients with dementia with Lewy bodies and Parkinson disease dementia have severe, sometimes life-threatening sensitivity to D2 blockade; haloperidol and risperidone should be avoided.^[36]
• Quetiapine and pimavanserin are preferred for behavioral disturbance in these populations, though both carry their own risks and FDA boxed warnings for increased mortality in dementia-related psychosis apply.^[36]

Comorbid substance use

• Cocaine, methamphetamine, and synthetic cathinones ("bath salts") can produce parkinsonism either acutely or via long-term dopaminergic injury.^[26]
• Alcohol withdrawal can mimic tremor but lacks the bradykinesia of true parkinsonism.^[26]

Outcome depends primarily on whether the offending agent can be removed or substituted. Most patients improve substantially within weeks of drug discontinuation, but a meaningful minority have persistent symptoms suggesting unmasked primary disease.^[1,8,19]

Recovery trajectory

• 60-70% of patients have substantial improvement within 4-8 weeks of stopping the offending agent.^[1,19]
• 10-15% have symptoms persisting beyond 6 months, warranting reassessment for idiopathic Parkinson disease.^[8,19]
• Long-acting injectable antipsychotics may produce prolonged symptoms reflecting their slow release; benztropine or amantadine may be needed for months.^[19]

Relapse and conversion

• Re-exposure to a dopamine blocker reliably reproduces symptoms in susceptible patients.^[1]
• Cohort studies suggest 10-20% of patients with apparent drug-induced parkinsonism convert to a clinical idiopathic Parkinson disease diagnosis over 5-10 years.^[8]
• Abnormal DaT-SPECT in a patient with apparent drug-induced parkinsonism strongly predicts subsequent conversion.^[15]

Functional outcomes

• Most patients recover baseline function with drug withdrawal, but older adults often experience persistent gait disturbance and fall risk even after motor signs improve.^[33]
• Adherence to subsequent antipsychotic therapy improves when parkinsonism is acknowledged and treated rather than dismissed.^[31]

Pure drug-induced parkinsonism is rarely a medical emergency, but it occupies clinical airspace adjacent to two emergencies — neuroleptic malignant syndrome and acute dystonic reaction — and contributes to fall and aspiration risk in vulnerable patients.^[23,33]

Distinguishing from neuroleptic malignant syndrome

• NMS presents with fever above 38°C, severe rigidity, autonomic instability (tachycardia, labile BP, diaphoresis), and altered mental status alongside markedly elevated creatine kinase.^[23]
• Drug-induced parkinsonism lacks fever, autonomic instability, and altered mental status; CK may be mildly elevated but not the 1000+ U/L range typical of NMS.^[23]
• When in doubt, stop the offending agent, support volume status, monitor temperature and CK, and consider transfer to higher level of care.^[23]

Fall and aspiration risk

• Bedside swallowing assessment is warranted in patients with severe drug-induced parkinsonism, particularly older adults.^[33]
• Fall prevention measures (physical therapy referral, environmental modification, medication review) reduce morbidity during the symptomatic period.^[33]

When hospitalization is needed:

• Severe parkinsonism with inability to ambulate, swallow safely, or care for self.^[33]
• Suspected NMS or other neuroleptic emergency.^[23]
• Need for inpatient antipsychotic adjustment in a patient with poorly controlled underlying psychosis.^[28]

Several practical questions in the management of drug-induced parkinsonism remain unsettled and reflect genuine evidence gaps rather than guideline disagreement alone.^[19,27]

Active areas of debate

• Whether routine anticholinergic prophylaxis at antipsychotic initiation should be abandoned entirely or retained for narrowly defined high-risk groups; guidelines disagree on the threshold.^[27]
• The appropriate duration of anticholinergic therapy once started — long-term use is associated with cognitive decline, but premature withdrawal can trigger symptom rebound.^[27,30]
• Whether long-acting injectables produce qualitatively different parkinsonism (more protracted, less responsive to discontinuation) or merely the same syndrome with a prolonged pharmacokinetic tail.^[19]
• The role of DaT-SPECT in routine practice — sensitive but expensive and not universally available; current guidelines reserve it for diagnostic uncertainty.^[15]
• Whether VMAT2 inhibitors used for tardive dyskinesia (valbenazine, deutetrabenazine) cause clinically meaningful parkinsonism in clinical practice, given their dose-dependent dopamine depletion mechanism.^[11]

Emerging considerations

• D2 partial agonists (aripiprazole, brexpiprazole, cariprazine) carry lower but real parkinsonism risk; long-term comparative data are still maturing.^[14]
• Pimavanserin (5-HT2A inverse agonist with no D2 activity) avoids parkinsonism but has its own FDA boxed warning for mortality in dementia-related psychosis.^[36]
• Genetic predictors of susceptibility (CYP2D6, DRD2 variants) may eventually inform agent selection but are not yet ready for routine use.^[16]

• Drug-induced parkinsonism is the second most common drug-induced movement disorder after akathisia and the second most common cause of parkinsonism after idiopathic Parkinson disease.^[1-2]
• Symptoms emerge within days to three months of starting or increasing a dopamine-blocking agent.^[1,17]
• Bradykinesia, rigidity, postural tremor, and postural instability are the cardinal features — the same TRAP tetrad as idiopathic Parkinson disease.^[20]
• Symmetric onset and prominent postural tremor favor drug-induced over idiopathic disease, which is classically asymmetric with a resting pill-rolling tremor.^[1,8]
• D2 receptor occupancy above 78-80% is the threshold above which EPS rise sharply.^[6]
• Highest-risk antipsychotics are high-potency first-generation agents (haloperidol, fluphenazine) and risperidone above 6 mg/day; lowest risk are clozapine and quetiapine.^[3-4]
• Metoclopramide and prochlorperazine are common non-psychiatric culprits; always review the antiemetic list.^[7]
• DaT-SPECT is normal in pure drug-induced parkinsonism and abnormal in idiopathic disease.^[15]
• First-line management is reduction or discontinuation of the offending agent; symptomatic treatment is added when this is impossible.^[19,27]
• Benztropine and trihexyphenidyl are first-line symptomatic agents but should be avoided in older adults due to anticholinergic harm; amantadine is the preferred alternative.^[27,30]
• Routine anticholinergic prophylaxis at antipsychotic initiation is no longer recommended.^[27]
• Persistent symptoms beyond 6 months after drug withdrawal raise concern for unmasked idiopathic Parkinson disease.^[8,19]
• The Simpson-Angus Scale is the workhorse rating instrument; a score above 3 is clinically meaningful.^[20]
• Patients with dementia with Lewy bodies have severe sensitivity to D2 blockade; haloperidol and risperidone are contraindicated.^[36]
• NMS is distinguished from severe drug-induced parkinsonism by fever, autonomic instability, altered mental status, and markedly elevated creatine kinase.^[23]

No external funding. No conflicts of interest declared. Peer-review status: internal draft, awaiting external clinical review.